cabergoline

(redirected from Dostinex)

cabergoline

 [cah-ber´go-lēn]
a dopamine receptor agonist used in treatment of hyperprolactinemia; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

cabergoline

A selective, potent, long-acting dopamine antagonist that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinaemic amenorrhoea; it is more effective and better tolerated than bromocriptine, which must be injected 2–3 times/day, compared to 1–2 weekly for cabergoline.

Adverse effects
Severe allergic reactions, chest tightness, behavioural changes (e.g., aggression, increased gambling or sexual urges, confusion, depression), hallucinations, chest pain, cough, arrhythmias, shortness of breath, unexplained weight gain, acral oedema, vision disturbances.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

cabergoline

Dostinex® A selective, potent, long-acting dopamine antagonist that suppresses prolactin secretion and restores gonadal function in ♀ with hyperprolactinemic amenorrhea; it is more effective and better tolerated than bromocriptine
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

cabergoline

A dopamine agonist drug used to treat breast disorders and to stop LACTATION soon after delivery. A brand name is Dostinex.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Bromocriptine * Cydoset, Parlodel Cabergoline * Dostinex Lamotrigine * Lamictal Lithium * Eskalith, Lithobid Olanzapine * Zyprexa Quetiapine * Seroquel
In connection with Watson's acquisition of Arrow Group, Impax acquired from Watson its ANDA for Cabergoline, the generic equivalent to Dostinex, and from Cobalt Pharmaceuticals its pending ANDA for Dronabinol, the generic equivalent to Marinol.
Cabergoline, which is marketed under the trade name Dostinex, is approved by the Food and Drug Administration in pill form to treat conditions caused by excess of the hormone prolactin.
Recently launched products include Zolpidem Tartrate tablets, AB-rated and bioequivalent to sanofi-aventis' Ambien; Azithromycin for injection; Cabergoline tablets, AB-rated and bioequivalent to Pfizer's Dostinex; and Moexipril Hydrochlorothiazide tablets, AB-rated and bioequivalent to Schwarz Pharma's Uniretic.
Cabergoline, which is marketed as Dostinex, is manufactured by Pfizer Inc.
A Pfizer spokesperson noted that the FDA approved Pfizer's revised label for Dostinex (cabergoline) in December and has already posted it on their Web site, www.fda.gov.
In a 6-month trial comparing the long-acting dopamine agonist cabergoline (Dostinex) with controlled-release levodopa, cabergoline was significantly better at reducing painful akinesia/dystonia, muscle spasms, and early morning akinesia, said Dr.
She was treated first with bromocriptine, and after her prolactin levels failed to return to normal, she was placed on cabergoline (Dostinex) 0.25 mg.
She reported on 86 patients with moderate to severe idiopathic restless leg syndrome who were randomized to placebo or to 0.5, 1.0, or 2.0 mg of cabergoline (Dostinex) in the evening in a 5-week double-blind dose-finding study
The New England Journal of Medicine (NEJM) recently reported that cabergoline (Dostinex [R]), a drug commonly used as an adjuvant therapy for men with prostate cancer, may cause heart valve damage.*